Pfizer (NY:PFE)

27.41 -0.39 (-1.40%)

Official Closing Price Updated: 4:03 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗

September 08, 2026

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Via The Motley Fool

Topics Intellectual Property

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 08, 2026

From Pfizer Inc.

Via Business Wire

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗

September 07, 2026

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Via The Motley Fool

This Is What I'd Do With Pfizer Stock Right Now ↗

September 07, 2026

The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 04, 2026

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Via The Motley Fool

Topics Intellectual Property

3 Things You Need to Know If You Buy Pfizer Stock Today ↗

September 03, 2026

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime...

Via The Motley Fool

Topics Intellectual Property

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion ↗

September 03, 2026

Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.

Via Benzinga

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

The company is coming back into the spotlight thanks to recent developments.

Via The Motley Fool

Wednesday's session: most active stock in the S&P500 index ↗

September 02, 2026

Via Chartmill

Should You Buy Pfizer Stock Below $30? ↗

September 02, 2026

Patient investors who buy the stock may be rewarded over the long term.

Via The Motley Fool

Topics Earnings Intellectual Property

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

September 02, 2026

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Via The Motley Fool

Top Companies Using Salesforce CRM in the USA ↗

September 02, 2026

Salesforce powers the engine behind America’s most ambitious brands. From retail giants to global banks, its footprint is massive. Therefore, marketers eve

Via Talk Markets

Curious about the most active S&P500 stocks in today's session? ↗

September 01, 2026

Via Chartmill

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

August 31, 2026

Via Chartmill

3 Stocks for Investors Who Still Believe Cash Is King ↗

August 31, 2026

As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.

Via MarketBeat

Topics Artificial Intelligence ETFs Economy

3 Cash-Producing Stocks That Concern Us

August 31, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Via The Motley Fool

2 Cash-Producing Stocks with Solid Fundamentals and 1 We Turn Down

August 28, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax ↗

August 27, 2026

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.

Via Benzinga

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

August 27, 2026

From Pfizer Inc.

Via Business Wire

The Most Concerning Thing About Pfizer's Dividend Isn't What You Think ↗

August 27, 2026

Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now.

Via The Motley Fool

Topics Intellectual Property

Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session. ↗

August 26, 2026

Via Chartmill

My 2 Favorite Dividend Stocks to Buy in August ↗

August 26, 2026

These are two stocks that pay investors a regular income.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Stocks to Hold for the Next 10 Years ↗

August 25, 2026

These healthcare leaders are unlikely to suspend their dividend programs.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks

August 24, 2026

Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin...

Via StockStory

Topics Artificial Intelligence Intellectual Property

D-Wave Quantum vs. Rigetti Computing: Which Quantum Computing Stock Is a Better Investment in 2026? ↗

August 24, 2026

While both D-Wave and Rigetti's revenues have been volatile, their valuations tell a starkly different story for quantum investors.

Via The Motley Fool

Prediction: This Is Where Pfizer Stock Will Be in 2030 ↗

August 22, 2026

Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.

Via The Motley Fool

Topics Intellectual Property

The Dividend ETF That Generates Passive Income While You Sleep ↗

August 21, 2026

Income generation is more about finding consistency than finding an ultra-high yield.

Via The Motley Fool

Topics ETFs

3 of Wall Street’s Favorite Stocks We’re Skeptical Of

August 21, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.